| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $80.0M | -3.8% |
| SG&A Expense | $18.0M | +12.5% |
| Operating Income | -$98.1M | +1.2% |
| Net Income | -$100.5M | -7.4% |
| EPS (Basic) | -$1.00 | +52.6% |
| EPS (Diluted) | -$1.00 | +52.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $35.7M | -23.6% |
| Current Assets | $39.3M | -25.1% |
| Total Assets | $40.9M | -24.7% |
| Current Liabilities | $22.2M | -10.3% |
| Total Liabilities | $22.4M | -11.5% |
| Stockholders' Equity | $18.4M | -36.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$84.8M | -19.7% |
| Capital Expenditures | $264K | -21.0% |
| Investing Cash Flow | -$264K | -102.8% |
| Financing Cash Flow | $74.5M | +7116.0% |
| Free Cash Flow | -$85.0M | -19.5% |